# Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

> **NCT01345929** · PHASE3 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 558 (actual)

## Conditions studied

- Complicated Urinary Tract Infection
- Pyelonephritis

## Interventions

- **DRUG:** CXA-201
- **DRUG:** Levofloxacin

## Key facts

- **NCT ID:** NCT01345929
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-20
- **Primary completion:** 2013-08-11
- **Final completion:** 2013-09-04
- **Target enrollment:** 558 (ACTUAL)
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345929, "Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01345929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*